Latest Eisai Co. Ltd. Stories

2011-04-22 04:35:01

Tokyo, Apr 22, 2011 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) announced today that it has received approval to market its novel anticancer Halaven(R) Injection 1mg (eribulin mesylate) in Japan for the treatment of inoperable and recurrent breast cancer.

2010-09-30 08:35:01

Tokyo, Sept 29, 2010 - (JCN Newswire) - Eisai Co., Ltd. and Shinshu University venture company Anaeropharma Science, Inc.

2010-09-30 08:35:01

Tokyo, Sept 30, 2010 - (JCN Newswire) - Brain Factory Co., Ltd. and Eisai Co., Ltd. announced today that they have concluded a license agreement concerning a dihydrogen phosphonoxy methoxy derivative of ravuconazole (ravuconazole prodrug).

2010-09-07 04:35:02

Tokyo, Sept 7, 2010 - (JCN Newswire) - SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd.

2010-09-02 04:35:01

Tokyo, Sept 2, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer's disease.

2010-08-26 03:13:34

Tokyo, Aug 24, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today that results of a Phase III study in epilepsy patients with refractory partial seizures demonstrate the clinical benefits of the novel investigational compound E2007 (generic name: perampanel).

2009-07-15 07:00:00

EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc.

2009-07-08 08:49:00

WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S.

Word of the Day
  • Large; stout; burly.
The word 'bowerly' is an alteration of 'burly'.